These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 25141273)

  • 1. Risk of bias in trial-based economic evaluations: identification of sources and bias-reducing strategies.
    Evers SM; Hiligsmann M; Adarkwah CC
    Psychol Health; 2015 Jan; 30(1):52-71. PubMed ID: 25141273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of bias in model-based economic evaluations: the ECOBIAS checklist.
    Adarkwah CC; van Gils PF; Hiligsmann M; Evers SM
    Expert Rev Pharmacoecon Outcomes Res; 2016 Aug; 16(4):513-23. PubMed ID: 26588001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic Impact of Third-Wave Cognitive Behavioral Therapies: A Systematic Review and Quality Assessment of Economic Evaluations in Randomized Controlled Trials.
    Feliu-Soler A; Cebolla A; McCracken LM; D'Amico F; Knapp M; López-Montoyo A; García-Campayo J; Soler J; Baños RM; Pérez-Aranda A; Andrés-Rodriguez L; Rubio-Valera M; Luciano JV
    Behav Ther; 2018 Jan; 49(1):124-147. PubMed ID: 29405918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of factorial randomised controlled trials: challenges, methods and recommendations.
    Dakin H; Gray A
    Stat Med; 2017 Aug; 36(18):2814-2830. PubMed ID: 28470760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing the risk of bias in health behaviour change trials: improving trial design, reporting or bias assessment criteria? A review and case study.
    de Bruin M; McCambridge J; Prins JM
    Psychol Health; 2015 Jan; 30(1):8-34. PubMed ID: 25112431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are current standards of reporting quality for clinical trials sufficient in addressing important sources of bias?
    Mills EJ; Ayers D; Chou R; Thorlund K
    Contemp Clin Trials; 2015 Nov; 45(Pt A):2-7. PubMed ID: 26232560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical review of economic evaluations in multiple myeloma: an overview of the economic evidence and quality of the methodology.
    Gaultney JG; Redekop WK; Sonneveld P; Uyl-de Groot CA
    Eur J Cancer; 2011 Jul; 47(10):1458-67. PubMed ID: 21561761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relevance of searching for effects under a clinical-trial lamppost: a key issue.
    Rittenhouse BE
    Med Decis Making; 1995; 15(4):348-57. PubMed ID: 8544678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors to consider when designing phase III clinical trials involving economic evaluations.
    van Enckevort PJ; TenVergert EM; Kingma J; Koëter GH; Rutten FF
    Percept Mot Skills; 1999 Dec; 89(3 Pt 2):1059-72. PubMed ID: 10710753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trials with concurrent economic evaluations reported unrepresentatively large clinical effect sizes.
    Gilbody S; Bower P; Sutton AJ
    J Clin Epidemiol; 2007 Aug; 60(8):781-6. PubMed ID: 17606173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analyses of cost data in economic evaluations conducted alongside randomized controlled trials.
    Doshi JA; Glick HA; Polsky D
    Value Health; 2006; 9(5):334-40. PubMed ID: 16961551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Occupational Therapy in Older People: Systematic Review of Randomized Controlled Trials.
    Nagayama H; Tomori K; Ohno K; Takahashi K; Yamauchi K
    Occup Ther Int; 2016 Jun; 23(2):103-20. PubMed ID: 26381549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?
    Dodd LE; Korn EL; Freidlin B; Jaffe CC; Rubinstein LV; Dancey J; Mooney MM
    J Clin Oncol; 2008 Aug; 26(22):3791-6. PubMed ID: 18669467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Menopausal hormone therapy: a systematic review of cost-effectiveness evaluations.
    Velentzis LS; Salagame U; Canfell K
    BMC Health Serv Res; 2017 May; 17(1):326. PubMed ID: 28476121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluations of smoking cessation and relapse prevention programs for pregnant women: a systematic review.
    Ruger JP; Emmons KM
    Value Health; 2008; 11(2):180-90. PubMed ID: 17854435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.
    Ramsey SD; Willke RJ; Glick H; Reed SD; Augustovski F; Jonsson B; Briggs A; Sullivan SD
    Value Health; 2015 Mar; 18(2):161-72. PubMed ID: 25773551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches.
    Hughes D; Charles J; Dawoud D; Edwards RT; Holmes E; Jones C; Parham P; Plumpton C; Ridyard C; Lloyd-Williams H; Wood E; Yeo ST
    Pharmacoeconomics; 2016 May; 34(5):447-61. PubMed ID: 26753558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of nurse practitioner and clinical nurse specialist roles: A methodological review.
    Lopatina E; Donald F; DiCenso A; Martin-Misener R; Kilpatrick K; Bryant-Lukosius D; Carter N; Reid K; Marshall DA
    Int J Nurs Stud; 2017 Jul; 72():71-82. PubMed ID: 28500955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach (part 1/3).
    van Mastrigt GA; Hiligsmann M; Arts JJ; Broos PH; Kleijnen J; Evers SM; Majoie MH
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):689-704. PubMed ID: 27805469
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.